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Abstract
Background: The airway epithelium of chronic obstructive pulmonary disease (COPD) patients undergoes aberrant
repair and remodeling after repetitive injury following exposure to environmental factors. Abnormal airway
regeneration observed in COPD is thought to originate in the stem/progenitor cells of the airway epithelium, the
basal cells (BCs). However, the molecular mechanisms underlying these changes remain unknown. Here, trophoblast
cell surface antigen 2 (TROP2), a protein implicated in the regulation of stem cell activity, was examined in lung
tissue samples from COPD patients.
Methods: The expression of TROP2 and hyperplasia index Ki67 was assessed in lung epithelium specimens from
non-smokers (n = 24), smokers (n = 24) and smokers with COPD (n = 24). Primary airway BCs were isolated by
bronchoscopy from healthy individuals and COPD patients and subsequently transfected with pcDNA3.1-TROP2 or
siRNA sequence in vitro. The functional consequences of TROP2 overexpression in BCs were explored.
Results: Immunohistochemistry and immunofluorescence revealed increased TROP2 expression in airway BCs in
smokers with COPD compared to nonsmokers and smokers without COPD, and staining was highly localized to
hyperplastic regions containing Ki67 positive cells. TROP2 expression was also inversely correlated with airflow
limitation in patients with COPD (r = −0.53, P < 0.01). pcDNA3.1-TROP2-BCs in vitro exhibited improved proliferation
with activation of ERK1/2 phosphorylation signaling pathway. In parallel, changes in vimentin and E-cadherin in
pcDNA3.1-TROP2-BCs were consistent with an epithelial-mesenchymal transition (EMT)-like change, and secretion of
inflammatory factors IL-1β, IL-8 and IL-6 was increased. Moreover, down-regulation of TROP2 by siRNA significantly
attenuated the proliferation of BCs derived from COPD patients. EMT-like features and cytokine levels of COPD basal
cells were also weakened following the down-regulation of TROP2.
Conclusion: The results indicate that TROP2 may play a crucial role in COPD by affecting BC function and thus
airway remodeling through increased BC hyperplasia, EMT-like change, and introduction of inflammatory molecules
into the microenvironment.
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Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive degenerative lung disease and currently the
fourth leading cause of death worldwide [1]. Cigarette
smoke and other toxic particles are major risk factors
for the development of COPD. A critical feature of
COPD is airway remodeling, which is characterized by
aberrant repair of the epithelium and accumulation of fi-
broblasts [2, 3]. As airway epithelium is the primary tar-
get of inhaled harmful particles, abnormal tissue repair
has become a primary focus in understanding the
process of airway remodeling [4].
The airway epithelium consists of four types of cells,
including basal cells (BCs), ciliated cells, secretory cells
and neuroendocrine cells [5]. BCs include multipotent
stem/progenitor progenitor cells of bronchial airway epi-
thelium and make a major contribution to the regener-
ation of bronchial epithelium [6, 7]. These cells play a
key role in the maintenance of the normal airway epithe-
lial architecture through their capacity to self-renew, dif-
ferentiate into ciliated and secretory cells, and establish
interactions with mesenchymal cells [8–11]. Abnormal-
ities in the number and function of BCs may therefore
severely affect the regeneration of injured airway epithe-
lium such as in smoking. Basal cell hyperplasia caused
by smoking has occurred long before lung function de-
clines, indicating that the development of COPD may
begin with these cells [12]. However, little is known
about the molecular mechanisms underlying the abnor-
mal biological behavior of BCs in COPD.
Trophoblast cell surface antigen 2 (TROP2), is a type I
transmembrane glycoprotein with low to no expression
in normal tissues. It provides crucial signals for cells
with requirements for self-renewal, survival, and inva-
sion [13, 14]. Although TROP2 has been reported to be
highly expressed in various types of epithelial cancers,
including colorectal cancer, pancreatic cancer, and oral
squamous-cell carcinoma [15–18], TROP2 expression
has also been found in stem cells in various tissue types.
In human and mouse prostate, the TROP2 expressing
subpopulation of BCs possess stem cell capacities such
as self-renewal, regeneration and differentiation [19, 20].
Undifferentiated oval cells express TROP2 shortly after
activation due to liver injury [21]. TROP2 is also
enriched in endometrial-regenerating cells in a dissoci-
ated cell tissue recombination assay [22].
These results indicate that TROP2 might play an im-
portant role more generally in the regulation of the
growth and regeneration of stem cells as well as serve as
a molecular marker of them in various adult tissues.
Here, protein expression of TROP2 was specifically ex-
amined in the development of COPD in smokers.
TROP2 was furthermore overexpressed in normal airway
BCs in vitro in order to identify potential biological and
molecular pathways regulated by the protein. Our results
demonstrate that increased expression of TROP2 occurs
in the BC compartment of lung tissue samples, indicat-
ing that the protein might play a role in aberrant airway
repair and remodeling that are characteristic of COPD.
Methods
Ethics statement
Protocols for recruitment of patients and healthy, non-
smoking individuals as well as the collection of tissue
samples and the analysis of patient data were approved
by the ethics committee at Qilu Hospital of Shandong
University (Jinan, Shandong, China). Written informed
consent was obtained from each individual for participa-
tion in the study.
Patients
Lung tissue samples were obtained from patients (n =
72) at Qilu Hospital of Shandong University (Jinan,
Shandong, China) during lobectomy or pneumonectomy
performed for medical reasons, including lung tumor,
pneumatocele and pulmonary cyst. No patient had re-
ceived corticosteroids (oral or inhaled) within 1 month
before tissue collection. The cohort consisted of smokers
with COPD (n = 24), smokers without COPD (n = 24),
and nonsmokers (n = 24) as controls. The diagnosis of
COPD was made according to the guidelines of the Glo-
bal Initiative for Chronic Obstructive Lung Disease
(GOLD) [1]. Tissue samples of ~15 - 25 mm in size (n =
2) were removed from the subpleural parenchyma of the
lobe at a distance of ≥ 5 cm from the margins of the dis-
eased areas in each patient. The inclusion criterium for
smokers with and without COPD was a smoking index
of > 10 pack-years which was calculated by multiplying
the number of cigarette packs consumed per day (20 cig-
arettes per pack) with the number of years of smoking.
Exclusion criteria were atopic diseases, allergic rhinitis,
asthma, diabetes, acute or chronic infections.
Immunohistochemistry and immunofluorescence
Serial sections (4 μm) were cut from paraffin embedded
lung samples, and antigen retrieval was carried out for
both immunohistochemistry and immunofluorescence
by steaming sections for 15 min in Citrate buffer
(pH 6.0). Immunostaining and visualization was per-
formed with the Biotin-Streptavidin HRP Detection Sys-
tems (SP) and a DAB color development kit (ZhongShan
Golden Bridge Biotechnology, Beijing, China), and the
primary antibodies used were TROP2 (5 μg/ml; RD Bio-
sciences, Temecula, NJ, USA) and Ki67 (1:100; Abcam,
Cambridge, MA, UK). The mean staining density of
TROP2 in airway epithelium was analyzed using Image-
Pro Plus 6.0 software. For immunofluorescence, sections
were incubated overnight at 4 °C with mixed primary
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antibodies, including anti-TROP2 (10 μg/ml) and anti-
cytokeratin 5 (1:200; Abcam) as a marker for basal cells.
For visualization, fluorescently-labeled secondary anti-
bodies were incubated with slides, and images were cap-
tured with a Laser confocal microscope (Olympus DP70
CCD camera, Tokyo, Japan). TROP2 was expressed as
mean staining density in the airway epithelium. Ki67
index was calculated as the percentage of Ki67 positively
stained cell compared with the airway epithelial cells.
The area of the airway epithelium and the number of
epithelial cells were evaluated using Image-Pro Plus 6.0
software (Media Cybernetics, Silver Spring, MD, USA).
The analysis of all slides was performed by an experi-
enced lung pathologist.
Isolation and culture of BCs
The primary epithelial cells were derived from healthy
donors (n = 6) and COPD patients (n = 4) (50 % ≤ FEV1
< 80 % predicted). All the donors were off corticosteroid
use in recent month. Airway epithelial cells were ob-
tained by gently brushing the airway epithelium from
the third- to fourth-order bronchi of healthy nonsmok-
ing volunteers using flexible bronchoscopy as previously
described [23]. Cells were collected and cultured in a
T25 cell culture flask with BEGM (Lonza, Basel,
Switzerland) in 5 % CO2 in a humidified chamber at
37 °C. The medium was changed after the first 12 h in
culture to remove unattached cells and thereafter, every
2–3 days. Experiments were performed on BCs at pas-
sage 2 or 3.
Cyto-immunofluorescence for the identification of BCs
After the first passage, BCs were seeded onto glass cover
slips in a 24-well plate and incubated for 24 h. Cells
were fixed in 4 % paraformaldehyde for 15 min and
blocked with normal goat serum for 30 min at 37 °C.
Cells were rinsed thoroughly with phosphate buffered
saline (PBS) and incubated with primary antibody
against Cytokeratin 5 (1:100; Abcam) and p63 (1:100;
ZhongShan Golden Bridge Biotechnology) overnight at
4 °C. Slides were rinsed, incubated with TRITC conju-
gated anti-rabbit IgG (1:500; Beyotime, Beijing, China)
and FITC conjugated anti-mouse IgG at room
temperature for 30 min, counterstained with DAPI, and
visualized with confocal fluorescence microscopy.
Transfection
BCs were plated at a density of 105 cells/well on a 24-
well plate. After 24 h, cells were transfected with
pcDNA3.1-TROP2 or siRNA sequence (5′-GCACGCU-
CAUCUAUUACCUTT-3′, 5′-AGGUAAUAGAUGAGC-
GUGCTT-3′) using Lipofectamine™ 2000 Transfection
Reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. Cells transfected with
empty vector or scrambled siRNA were considered as
negative control. At 48 h, cells were trypsinized, and ex-
periments were performed.
Quantitative real-time PCR
Total RNA was extracted from harvested cells using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. First strand
cDNA was synthesized from RNA (1 μg) using the
ReverTra Ace® qPCR RT Kit (TOYOBO, Osaka City,
Japan). Real-time PCR reactions (20 μL) were prepared
using 2 μL of cDNA in SYBR® Green Real time PCR
Master Mix (TOYOBO), and amplification was per-
formed on an ABI PRISM 7900 HT Sequence Detection
System (Applied Biosystems, Foster City, CA, USA).
Relative quantification of mRNA was performed using
the comparative CT method where endogenous GAPDH
was used as the normalization control. The primer





Results were obtained from three independent experi-
ments performed in triplicate.
Western blot analysis
Cell extracts were prepared by lysing cells in ice-cold
RIPA buffer (20 mM sodium phosphate, 150 mM
NaCl, pH 7.4, 1 NP-40, 0.1 SDS and 0.5 % deoxy-
cholic acid) containing the protease inhibitor PMSF
(Beyotime). Proteins (40 μg) were separated on 10 %
SDS PAGE and transferred to PVDF membranes, and
the blots were incubated with antibodies against
human TROP2 (1 μg/ml), cyclin D1 (1:1000; Beyo-
time), E-cadherin (1:50000; Abcam), vimentin (1:500;
Abcam) and GAPDH (1:2000; GoodhereBiotech Co.,
Hangzhou, China) as the protein loading control.
Experiments were carried out in triplicate and re-
peated between three to five times.
Cell proliferation and viability assay
Cell viability was assessed using a colorimetric assay,
Cell Counting Kit-8 (CCK-8), according to the manufac-
turer’s instructions (Bestbio, Shanghai, China). Briefly,
transfected and control cells were seeded onto 96-well
plates at a density of 8000 cells/well and incubated in
5 % CO2 in a humidified chamber at 37 °C for 24, 48 or
72 h. At designated time intervals, CCK-8 solution
(10 μL) was added to each well, and the optical density
(O.D.) was measured at 450 nm in a microplate reader
(Bio-Rad Model 680, Richmond, CA, USA) after a 3 h
incubation at 37 °C. Experiments were repeated three
times and six parallel holes were set in each experiment.
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Cell cycle analysis
Cells were transfected with pcDNA3.1-TROP2 or with
siRNA sequence, harvested 48 h after transfection by
trypsinization, and fixed in 75 % cold ethanol for 1 h at
−20 °C. The cells were pelleted, rinsed with PBS, and in-
cubated with 100 μL RNase A (100 mg/mL) and 400 μL
propidium iodide for 30 min at 37 °C. Cell cycle analysis
was performed on the FACSCalibur flow cytometer
(Becton Dickinson, San Jose, CA, USA) at 488 nm. The
relative ratios of the G1, S, and G2 phases were analyzed
with ModFit LT 4.0 software. The assay was done in tripli-
cate and repeated in three independent experiments.
Wound repair
BCs were seeded onto 6-well plates, incubated overnight,
and transfected with pcDNA3.1-TROP2 or with siRNA
sequence. After reaching 90 % confluency, cell mono-
layers were scratched with a sterile pipette tip. Floating
cells were removed with PBS and reseeded in BEGM
medium. Images were taken at 0, 24 and 48 h to docu-
ment the rate of migration of cells into the wound. Re-
sults were expressed as the ratio of the wound area
detected at the designated time interval relative to the
original scratch area. Repair was quantified using Image-
Pro Plus software (Media Cybernetics, Rockville, MD,
USA). Experiments were carried out in triplicate and re-
peated three times.
Enzyme linked immunosorbent assay (ELISA)
Cells were transfected with pcDNA3.1-TROP2 or with
siRNA sequence. The supernatants were harvested 48 h
later, and the levels of IL-6, IL-8, and IL-1β were quanti-
fied in the supernatants using an ELISA kit according to
the manufacturer’s instructions (RD Biosciences). The
ELISA assay results were obtained from three independ-
ent experiments performed in triplicate.
Statistical analysis
SPSS version 18.0 (SPSS Inc.; Chicago, IL, USA) was
used to perform statistical analysis. All data were
expressed as the mean ± the standard deviation (SD).
The Kruskal–Wallis and Mann–Whitney U-tests were
used for comparisons between patient groups, and
correlation analyses were performed with Spearman rank
correlation. The Student’s t test was used for analysis of




Clinical characteristics and functional evaluation of the
patient study groups are shown in Table 1. Importantly,
the age range across the three patient groups was statis-
tically similar, including that of the control nonsmoking
group (P = 0.74). As patients with severe COPD could
not tolerate thoracotomy surgery, they were not con-
cerned in this study. As expected, the forced expiratory
volume in first second percentage (FEV1%) of predicted
and the FEV1/forced vital capacity (FVC) ratios were sig-
nificantly reduced in smoking patients with COPD
compared to healthy controls (P < 0.01 for both compari-
sons). The values in the FEV1% of predicted and the
FEV1/FVC ratios were statistically similar between
smokers without COPD and nonsmokers (P = 0.41 and
P = 0.30, respectively). Although the smoking index in
smokers with COPD seems to be a little higher than that
in smokers without COPD, there was no statistical sig-
nificance (P = 0.10).
TROP2 expression is elevated in airway BCs in COPD lung
tissue samples
To study the potential role of TROP2 in the develop-
ment of COPD, immunohistochemistry was used to
compare TROP2 expression in lung tissue samples from
smokers with COPD, smokers without COPD and non-
smokers (Fig. 1a). TROP2 was found to be expressed in
airway epithelium of all patient samples. While only
slight positivity of TROP2 was observed at the basolat-
eral cytoplasmic membrane in bronchial epithelium of
non-smokers, TROP2 was found to be highly expressed
in airway epithelium of all smokers, especially in those
patients with COPD (Fig. 1a). Quantitative analysis of
the immunostaining revealed that TROP2 expression
was significantly increased in COPD relative to
Table 1 Patient clinical and functional characteristics
Non-smokers Smokers Smokers with COPD
n 24 24 24
Sex (male/female) 20/4 19/5 19/5
Age (yr) 57.38 ± 9.36 55.58 ± 8.69 57.21 ± 8.28
Smoking index (pack-years) 0 34.79 ± 18.44 43.73 ± 16.00
FEV1 (% predicted) 98.49 ± 12.03 96.12.70 ± 8.01 63.24 ± 11.03
*#
FEV1/FVC (%) 82.24 ± 6.02 80.54 ± 5.78 54.16 ± 8.38
*#
COPD, chronic obstructive pulmonary disease, FEV1 forced expiratory volume in first second, FVC forced vital capacity. Data are expressed as the mean ± SD.
*P < 0.01 vs non-smokers; #P < 0.01 vs smokers without COPD
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nonsmoker and smoker controls as well as in smoker
controls relative to nonsmokers (P < 0.01 for all; Fig. 1b).
One of the key findings of the immunostaining was
that TROP2 was highly localized to cells along the basal
membrane of the epithelium. To determine whether
TROP2 was expressed specifically by airway BCs, im-
munofluorescent double staining was performed with
cytokeratin 5, a molecular marker for BCs, and TROP2.
Indeed, TROP2 staining was coincident with cytokeratin
5, indicating that expression of the protein originated in
part from airway BCs (Fig. 1c).
TROP2 expression correlates with the degree of airflow
obstruction in COPD patients
Molecular markers are increasingly playing a role in the
pathologic and thus clinical diagnosis of disease. The
severity of post-bronchodilator FEV1% of predicted is
recommended for the assessment of COPD severity
according to GOLD. Therefore, correlation of the level
of TROP2 expression with FEV1% was examined in our
patient cohort. The analysis revealed a significant inverse
correlation between FEV1% and TROP2 expression, i.e.
increases in TROP2 were coordinate with a decreased
FEV1% of predicted (r = −0.53, P < 0.01; Fig. 2).
Increased TROP2 expression correlates with a high airway
proliferative index in COPD tissue samples
Airway epithelial hyperplasia is one of the key patho-
logical features of COPD. To explore a possible asso-
ciation of TROP2 with airway hyperplasia in COPD,
the localization of the proliferation marker Ki67 and
the percentage of Ki67 positive cells were compared
to immunostaining for TROP2 in patient samples.
The density of Ki67 positive cells was significantly
higher in hyperplasic epithelium of COPD patients
than that in normal airway epithelium, thus parallel-
ing the staining pattern of TROP2 (P < 0.01; Fig. 3a
and b). Analysis of immunostaining for the two
proteins revealed a statistically significant correlation
between increased TROP2 expression and Ki67
positive cells in COPD lung tissue samples (r = 0.878,
P < 0.01; Fig. 3c).
Fig. 1 TROP2 expression is elevated in airway epithelium in lung tissue samples from COPD patients. a Immunohistochemistry staining for TROP2
performed on sections from non-smokers, smokers without COPD and smokers with COPD. Paired low and high magnification images are shown
for each patient type to highlight localization of the staining. (a), (b), (c) × 100; (d), (e), (f) × 200; scale bars = 50 μm. b Quantification of TROP2
staining in sections from all patients (n = 72). c Immunofluorescent staining for TROP2 and cytokeratin 5 performed on sections from a smoker
with COPD and a non-smoker. *P < 0.01 vs non-smokers; #P < 0.01 vs smokers without COPD
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TROP2 promotes proliferation and wound closure in BCs
in vitro
Given the close association between elevated TROP2
expression and airway epithelial hyperplasia in COPD pa-
tient lung tissues, TROP2 might promote proliferation of
BCs in COPD patients. In order to begin to elucidate the
functional consequences of increased TROP2 expression,
an in vitro system was exploited. BCs were first isolated
from airway epithelium of healthy volunteers, cultured,
and characterized using immunofluorescent staining for
markers of airway BCs, cytokeratin 5 and p63 (Fig. 4a).
BCs were subsequently transfected with an expression
vector for TROP2, pcDNA3.1-TROP2. At 48 h post-
transfection, mRNA and protein levels of TROP2 were in-
creased by ~2.5 fold in BCs, as assessed by real-time PCR
and Western blots analysis (Fig. 4b and c).
Two assays were performed to assess the possible
function of TROP2 in promoting the proliferation of
BCs: the CCK-8 assay to measure cell viability which is
directly proportional to increases in cell number, and
flow cytometry to assess cell cycle progression. In the
CCK-8 assay, O.D. 450 values were increased in
pcDNA3.1-TROP2-BCs, indicating that cell viability was
significantly improved in these cells relative to controls
(P < 0.05; Fig. 5a). When coupled with cell cycle analysis,
the increases in O.D. 450 associated with TROP2 expres-
sion were found to be due to changes in cell cycle kinet-
ics. The percentage of cells in S and G2/M was
significantly increased in pcDNA3.1-TROP2-BCs relative
to control cells (P < 0.05; Fig. 5b and c).
Enhanced proliferation in COPD is a consequence of
perpetual wound healing or tissue repair occurring in
COPD tissues of patients. The function of increased
TROP2 expression in COPD was further investigated in
BCs in vitro in a wound healing assay. At 24 and 48 h
after wounding, pcDNA3.1-TROP2-BCs displayed an in-
creased capacity for wound closure relative to control
cells (P < 0.01; Fig. 5d). The increased wound healing re-
sponse upon TROP2 overexpression can be due to in-
creased proliferative responses.
Fig. 3 Expression of TROP2 correlates with proliferative index of airway epithelium based on Ki67. a Immunohistochemistry detecting Ki67
expression in sections of paraffin embedded lung tissues from patients as indicated. Positive staining for Ki67 correlates with the brown staining
from DAB. Original × 200; scale bars = 50 μm. b Quantitation of immunostaining for Ki67 in patient samples (n = 72) as indicated. The density of
Ki67 positive cells was significantly higher in hyperplasic epithelium of COPD patients than in normal airway epithelium (P < 0.01). c Correlation of
the level of TROP2 protein expression with Ki67 in COPD patient samples as determined by immunohistochemistry. Results indicated a positive
correlation between increased TROP2 and Ki67 positive cells. *P < 0.01 vs non-smokers; #P < 0.01 vs smokers without COPD
Fig. 2 Correlation between the level of TROP2 protein expression
based on immunostaining and FEV1%. Spearman rank correlation
was used to examine the relationship between TROP2 expression
and FEV1%. TROP2 expression is inversely correlated with FEV1%
(r = −0.53, P < 0.01)
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Down-regulated TROP2 decreases proliferation and
wound closure in COPD-derived BCs
In order to show the relevance of endogenous TROP2
expression, TROP2 was down-regulated by siRNA in
COPD-derived BCs. At 48 h post-transfection, the result
of real-time PCR and Western blots analysis showed that
mRNA and protein levels of TROP2 were decreased by
~4.5 fold in BCs (Fig. 6a and b).
The CCK-8 assay showed that cell viability of siRNA-
TROP2-BCs was significantly impaired compared with
controls (P < 0.05; Fig. 7a). Accordingly, the percentage
of cells in S was significantly decreased in siRNA-
TROP2-BCs relative to control cells (P < 0.05; Fig. 7b
and c). The wound healing assay revealed that, at 24 and
48 h after wounding, siRNA-TROP2- BCs exhibited a
weakened capacity for wound closure relative to control
cells (P < 0.05; Fig. 7d).
Activation of ERK/MAPK signaling stimulates BC
proliferation
Recent studies have linked TROP2 to the MAPK signal-
ing pathway in the regulation of the cell cycle and cell
proliferation. Western blot analysis was performed to
determine whether phosphorylation of ERK1/2 might
also contribute to the altered cell proliferation mediated
by TROP2 in airway BCs in vitro. At 48 h after transfec-
tion, protein levels of pERK1/2 were up-regulated in
pcDNA3.1-TROP2-BCs (Fig. 8a). Expression of cyclin
D1, a downstream molecule in the ERK1/2 MAPK sig-
naling pathway and a positive regulator of G1 to S phase
transition, was also increased significantly. A second ap-
proach to investigate the intersection of these pathways
was to treat pcDNA3.1-TROP2-BCs with a specific in-
hibitor of the MAPK pathway, U0126 (20 μM; Beyo-
time). Treatment with U0126 blocked the increase in
pERK1/2 and inhibited TROP2 mediated BC prolifera-
tion assessed by CCK-8 assay (Fig. 8b), indicating that
pERK1/2 might be involved in the signaling pathway.
TROP2 induces an epithelial-mesenchymal transition
(EMT)-like phenotype in proliferating airway BCs
EMT is an important pathological feature of airway re-
modeling which occurs in COPD, and it may be related to
altered fibrotic activity taking place in the sub-epithelial
tissue. TROP2 has in fact been reported to be involved in
inducing EMT in some epithelial cell types, and as such, is
a potential candidate gene involved in the phenomenon in
airway BCs. Western blot analysis was used to determine
protein levels of specific markers typically altered in EMT
in pcDNA3.1-TROP2-BCs and siRNA-TROP2-BCs in cul-
ture. Protein levels of the epithelial marker E-cadherin
was significantly decreased in pcDNA3.1-TROP2-BCs
relative to control cells (P < 0.01; Fig. 9a) whereas the
expression of the mesenchymal marker vimentin was
Fig. 4 BCs transfected with pcDNA3.1-TROP2 express TROP2 RNA and protein. a Immunofluorescent staining of cultures for the stem cell markers
p63 and cytokeratin 5 (red) to identify BCs isolated from airway epithelium of healthy volunteers. Cytokeratin 5 is expressed in the cytoplasm
while p63 is expressed in the nuclei. DAPI highlights nuclei of viable cells. Original × 200; scale bars = 50 μm. b mRNA expression of TROP2 in
pcDNA3.1-TROP2-BCs. Relative levels of TROP2 expression to GAPDH in the indicated cell types determined using the δCT in transfected vs control
cells. c Protein expression levels of TROP2 in pcDNA3.1-TROP2-BCs. Western blot prepared with cell lysates (40 μg) from transfected and control
cells and incubated with the antibodies indicated. Protein levels were quantitated by chemiluminescence with GAPDH used as the control for
protein loading. *P < 0.01 vs untransfected cells; #P < 0.01 vs pcDNA3.1-BCs
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increased (~2.5 fold; P < 0.01; Fig. 9a). In contrast, down-
regulation of TROP2 significantly increased E-cadherin
expression and decreased vimentin expression in COPD-
derived BCs (P < 0.01; Fig. 9b).
Secretion of proinflammatory cytokines is increased in
BCs overexpressing TROP2
An important factor contributing to significant changes
in tissue architecture is the secretion of proinflammatory
cytokines into the microenvironment. To determine
whether increased expression of TROP2 influenced se-
cretion of inflammatory factors from proliferating BCs,
the levels of inflammatory cytokines IL-6, IL-8, and IL-
1β were evaluated in supernatants from transfected BCs
in vitro. The levels of all three factors were increased in
the supernatants of pcDNA3.1-TROP2-BCs relative to
supernatants of control cells (P < 0.05 for all factors;
Fig. 10a). On contrary, after the TROP2 expression was
Fig. 5 TROP2 promotes BC proliferation and wound closure in vitro. a The O.D. 450 results from the CCK-8 viability assay are plotted as a function
of time for pcDNA3.1-TROP2-BCs and control cells. Cell viability in the pcDNA3.1-TROP2-BCs was significantly improved (P < 0.05). b, c Cell cycle
analysis of pcDNA3.1-TROP2-BCs and control cells. Distribution of cells in G1, S and G2/M phases as determined by flow cytometry are represented
graphically in a bar graph and in the standard flow diagram generated in the ModFit LT 4.0 software. d Images of wound healing assays and
quantitation of results performed on pcDNA3.1-TROP2-BCs and control cell types. (P < 0.01). *P < 0.05 vs untransfected cells; #P < 0.05 vs
pcDNA3.1-BCs; **P < 0.01 vs untransfected cells; ##P < 0.01 vs pcDNA3.1-BCs
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down-regulated by siRNA in COPD-derived BCs, the
levels of IL-6, IL-8, and IL-1β in supernatants were
significantly decreased (P < 0.05 for all factors; Fig. 10b).
Discussion
Airway BCs play crucial roles in epithelial regener-
ation and homeostasis following injury [24]. Disregu-
lated BC function has been demonstrated to be an
early event in the pathogenesis of COPD, based in
part on changes in BC transcription in smokers and
as the smoker transitions into clinically defined
COPD [25–27]. BC hyperplasia has been a histologic
abnormality associated with smoking [28], although
the reasons remain obscure. Because of its association
with proliferation and progenitor cells in mouse and
human, TROP2 was the focus of our study as a po-
tential regulator of the biological behavior of airway
BCs in COPD.
Our results demonstrated that TROP2 expression was
significantly increased in vivo in airway BCs of COPD
patients, and revealed a significant correlation between
TROP2 expression and the degree of airway epithelium
hyperplasia. In vitro, TROP2 promoted BC proliferation
and self-renewal mediated possibly through the ERK sig-
naling pathway. Finally, TROP2 induced an EMT-like
phenotype and release of proinflammatory cytokines in
proliferating BCs. These results indicate that increased
TROP2 protein in BCs might play a critical role in air-
way remodeling which is a key pathological feature of
COPD in patients.
Regulation of TROP2 gene expression has been
detected by DNA microarray analysis in cancer cells
[29]. Whereas little is known about the mechanisms that
could be responsible for the increased expression of
TROP2 in COPD epithelium. In our study, staining
intensity was generally greater in smokers regardless of
COPD status than in nonsmokers, indicating that
smoking alone was a risk factor up-regulating TROP2
expression. Smoking was not however the single contrib-
uting factor, as higher TROP2 expression was specifically
observed in patients with COPD. One explanation for
this result might be an individual genetic susceptibility
to COPD. Further research is necessary to investigate
the exact regulatory mechanism of TROP2 expression in
airway BCs. Further, the relationship between TROP2
and cell proliferation due to the expression of the
proliferation-related nuclear protein Ki67 was estab-
lished in this study. The significant correlation between
TROP2 and Ki67 expression supports the hypothesis
that overexpressed TROP2 is closely related to the
hyperproliferative state of airway epithelium in COPD.
The results from immunohistochemistry were further
supported by experiments performed in an in vitro sys-
tem, which revealed an enssential role that TROP2
played in airway BC proliferation. It has been reported
that U0126 (20 μM) is a more highly selective inhibitor
of MEK1/2, although it might have a very weak inhibi-
tory effect on PKC, Cdk2 and Cdk4 [30]. Therefore, our
result suggested that pERK1/2 MAPK signal pathway
might be involved in the process of TROP2-mediate BC
proliferation. The mechanism of TROP2-induced activa-
tion of pERK1/2 in BCs is unclear. It has been reported
that overexpressed TROP2 could increase the intracellu-
lar Ca2+ level, which was capable of activating the ERK
MAPK pathways through calmodulin-dependent protein
kinases [13]. TROP2 regulated cell self-renewal and pro-
liferation through a mechanism of regulated intramem-
brane proteolysis was found in prostate stem cells [14].
BC hyperplasia is a typical airway epithelial remodeling
phenotype in COPD lungs. The proliferation of BCs can
act as a benign protective cellular reaction to injury in
the airways of normal individuals, but it may also be the
cause of pathological changes occurring at an early stage
in COPD. BC hyperplasia in small airways could lead to
airway wall thickening, contributing to small airway
narrowing and airflow limitation [31]. Furthermore,
the increased number of BCs also gives rise to squa-
mous metaplasia in central airways, which is also an
early airway pathological change observed in COPD
patients [32, 33].
Fig. 6 Down-regulation of TROP2 by siRNA in COPD-derived BCs. a mRNA expression of TROP2 in siRNA-TROP2-BCs. b Protein expression levels of
TROP2 in siRNA-TROP2-BCs. *P < 0.01 vs untransfected cells; #P < 0.01 vs Scrambled-BCs
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BCs acquired EMT-like features during TROP2 medi-
ated proliferation, which was manifested by the de-
creased expression of epithelial cell markers cytokeratin
5 and E-cadherin and the acquisition of the mesenchy-
mal cell marker vimentin. Classical EMT refers to the
epithelial cells closely connected to the basement mem-
brane which lose polarity and acquire a mesenchymal
cell phenotype [34]. The EMT process is present in
bronchial epithelial cells of patients with COPD and has
a role in airway remodeling [35, 36]. Our findings indi-
cate that BCs may be one of the cell types undergoing
EMT. Consistent with this result, is that BCs have been
reported to undergo EMT-like changes in an acute lung
injury model of BC differentiation which was mediated
by EGF. Airway epithelium generated from the EGF-
exposed BCs also exhibited decreased barrier integrity
[37]. In addition, Jonsdottir et al. recently reported that
some p63-positive BCs are prone to phenotypic changes
and could act as EMT progenitors in idiopathic pulmon-
ary fibrosis [38].
Exposure to repetitive inflammatory stimuli leads to ex-
aggerated and persistent activation of the repair process
and is one of the primary causes of airway remodeling char-
acteristic of COPD [39, 40]. In our study, secretion of
Fig. 7 Down-regulated TROP2 decreases proliferation and wound closure in COPD-derived BCs. a Cell viability in the siRNA-TROP2-BCs was
significantly inhibited (P < 0.05). b, c Cell cycle analysis of siRNA-TROP2-BCs and control cells. d Images of wound healing assays and quantitation
of results performed on siRNA-TROP2-BCs and control cell types. *P < 0.05 vs untransfected cells; #P < 0.05 vs siRNA-BCs; **P < 0.01 vs untransfected
cells; ##P < 0.01 vs siRNA-BCs
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Fig. 9 The effect of TROP2 expression on EMT-like changes in BCs. Western blot analysis was performed on cell lysates (40 μg) prepared from cells
transfected with the pcDNA3.1 or the expression vector pcDNA3.1-TROP2 and control BCs. Blots were incubated with the antibodies as indicated
with GAPDH used as the control for protein loading. Protein levels indicated were quantitated based on chemiluminescence. a The protein levels
of the epithelial marker E-cadherin was significantly decreased in pcDNA3.1-TROP2-BCs (P < 0.01) whereas the expression of the mesenchymal
marker vimentin was increased compared to control cells (P < 0.01). *P < 0.01 vs untransfected cells; #P < 0.01 vs pcDNA3.1-BCs. b Down-
regulation of TROP2 significantly increased E-cadherin expression and decreased vimentin expression in COPD-derived BCs (P < 0.01).
*P < 0.01 vs untransfected cells; #P < 0.01 vs Scrambled-BCs
Fig. 8 Activation of the ERK/MAPK signaling pathway enhances proliferation of BCs. a Western blot analysis was performed on cell lysates (40 μg)
prepared from transfected (pcDNA3.1 and pcDNA3.2-TROP2) and control cells 48 h after transfection and inhibition of the ERK/MAPK pathway
with U0126 as indicated (+/−). Blots were incubated with the antibodies indicated. Protein levels were visualized with chemiluminescence, and
GAPDH was used as the control for protein loading. b O.D. 450 nm of CCK-8 was plotted as a function of time to assess viability/proliferation of
pcDNA3.1-TROP2-BCs treated with the ERK/MAPK pathway inhibitor U0126. *P < 0.05; **P < 0.01
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proinflammatory cytokines IL-6, IL-8, and IL-1β was in-
creased in TROP2 mediated proliferation of BCs. Elevated
levels of these proinflammatory factors have been con-
firmed in the airways of COPD patients. These cytokines
serve as effective chemokines, leading to the infiltration of
neutrophils and macrophages and the expansion of persist-
ent inflammatory injury to airway epithelium [41]. BCs are
not just cellular targets of the process of inflammation; BCs
also release chemokines and cytokines, thereby initiating
and orchestrating immune and inflammatory responses.
These data support the concept that the pathological
change secondary to altered BC proliferation leads to ab-
normal innate immunity, potentially contributing to the
pathologic cycle of chronic airway inflammation and re-
modeling in COPD.
One limitation of this study is that all the lung tissue
samples were collected from patients with mild to mod-
erate COPD, and severe COPD patients incapable of
undergoing surgery operation were not included. The
situation in severe COPD may be very different from the
relative early stage, in which the repairing ability of BCs
may be relative conserved. As Perotin et al. reported that
delayed rather than enhanced epithelial wound repair
was found in severe COPD [42]. Actually, we agree with
this idea. The explanation for this observation may be
that the renewal and regeneration capacity of BCs could
diminish due to excessive stem cell hyperproliferation
and eventual replicative senescence [43, 44]. And we also
observed a so-called aging of pcDNA3.1-TROP2-BCs in
culture in cells passaged > 5 generations. This finding
parallels the in vivo situation of COPD: an initial promo-
tion of BC proliferation followed by senescence or death
after extended time in the repair state. In addition, the
mechanism involved in TROP2 inducing EMT-like
changes and enhanced proinflammatory cytokines secre-
tion has not been deeply researched yet. pERK1/2
MAPK signal pathway was considered in the study. After
pre-treated with U0126, neither EMT makers nor proin-
flammatory cytokine concentrations underwent signifi-
cant changes in pcDNA3.1-TROP2-BCs (data not
shown), suggesting that pERK1/2 MAPK pathway may
not participate in the process. It is necessary to carry on
further researches in the subsequent studies.
Conclusions
In summary, the data presented in this study identify a po-
tential role for TROP2 overexpression in the pathogenesis
of COPD. TROP2 expression was particularly enriched in
airway BCs of patients with COPD, and in vitro, TROP2
overexpression induced changes in BCs that parallel air-
way remodeling in COPD. TROP2 might therefore play a
critical role in early airway repair abnormalities and
Fig. 10 The influence of TROP2 expression on secretion of proinflammatory cytokines in BCs. BCs were transfected with pcDNA3.1-TROP2 or
siRNA sequence. The concentrations of IL-1β IL-6, and IL-8 in supernatants of transfected and control cells were analyzed by ELISA and compared.
The results represent the mean ± SD of 3 measurements. a Secretion of IL-1β IL-6, and IL-8 was increased in BCs overexpressing TROP2. P < 0.05
for all factors. *P < 0.05 vs untransfected cells; #P < 0.05 vs pcDNA3.1-BCs. b Secretion of IL-1β IL-6, and IL-8 was significantly decreased in TROP2-
downregulated BCs (P < 0.05). *P < 0.01 vs untransfected cells; #P < 0.01 vs Scrambled-BCs
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remodeling in COPD patients. Further insight into the
function of TROP2 in BCs will provide potential strategies
for future therapy of COPD.
Abbreviations
BCs: Basal cells; COPD: Chronic obstructive pulmonary disease;
EMT: Epithelial-mesenchymal transition; ERK: Extracellular regulated protein
kinase; FEV1: Forced expiratory volume in first second; FVC: Forced vital
capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease;
TROP2: Trophoblast cell surface antigen 2
Acknowledgements
The authors thank the volunteers of the study for their willingness to
contribute to our medical research.
Funding
This work was supported by the National Natural Science Foundation of the
People’s Republic of China (grant 81170041; 81370148).
Authors’ contributions
QXL: participated in the design of the study, performed the histological cell
experiments, and drafted the manuscript. HJL: participated in tissue
processing, cell cultures, and statistical analysis. QW and YKZ: advised on cell
isolation and histology strategy. WW and SD: participated in cell cultures.
WX: conceived the study, participated in the design of the study and revised
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Protocols for recruitment of patients and healthy, nonsmoking individuals as
well as the collection of tissue samples and the analysis of patient data were
approved by the ethics committee at Qilu Hospital of Shandong University
(Jinan, Shandong, China). Written informed consent was obtained from each
individual for participation in the study.
Author details
1Department of Respiratory Medicine, Qilu Hospital, Shandong University,
107 Wenhua West Road, Jinan, China. 2Department of Cadre Health Care,
Qilu Hospital, Shandong University, 107 Wenhua West Road, Jinan, China.
3Department of Anesthesiology, Qilu Hospital, Shandong University, 107
Wenhua West Road, Jinan, China. 4Department of Cadre Health Care,
Qianfoshan Hospital, 16766 Jingshi Road, Jinan, China.
Received: 5 February 2016 Accepted: 1 November 2016
References
1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes
PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the
diagnosis, management, and prevention of chronic obstructive pulmonary
disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:
347–65.
2. Heijink IH, Brandenburg SM, Postma DS, van Oosterhout AJ. Cigarette
smoke impairs airway epithelial barrier function and cell-cell contact
recovery. Eur Respir J. 2012;39:419–28.
3. Proud D, Hudy MH, Wiehler S, Zaheer RS, Amin MA, Pelikan JB, Tacon CE,
Tonsaker TO, Walker BL, Kooi C, et al. Cigarette smoke modulates expression
of human rhinovirus-induced airway epithelial host defense genes. PLoS
One. 2012;7:e40762.
4. Tam A, Wadsworth S, Dorscheid D, Man SF, Sin DD. The airway epithelium:
more than just a structural barrier. Ther Adv Respir Dis. 2011;5:255–73.
5. Knight DA, Holgate ST. The airway epithelium: structural and functional
properties in health and disease. Respirology. 2003;8:432–46.
6. Hong KU, Reynolds SD, Watkins S, Fuchs E, Stripp BR. Basal cells are a
multipotent progenitor capable of renewing the bronchial epithelium. Am J
Pathol. 2004;164:577–88.
7. Hong KU, Reynolds SD, Watkins S, Fuchs E, Stripp BR. In vivo differentiation
potential of tracheal basal cells: evidence for multipotent and unipotent
subpopulations. Am J Physiol Lung Cell Mol Physiol. 2004;286:L643–649.
8. Evans MJ, Van Winkle LS, Fanucchi MV, Plopper CG. Cellular and molecular
characteristics of basal cells in airway epithelium. Exp Lung Res. 2001;27:
401–15.
9. Rock JR, Onaitis MW, Rawlins EL, Lu Y, Clark CP, Xue Y, Randell SH, Hogan
BL. Basal cells as stem cells of the mouse trachea and human airway
epithelium. Proc Natl Acad Sci U S A. 2009;106:12771–5.
10. Hajj R, Baranek T, Le Naour R, Lesimple P, Puchelle E, Coraux C. Basal cells of
the human adult airway surface epithelium retain transit-amplifying cell
properties. Stem Cells. 2007;25:139–48.
11. Boers JE, Ambergen AW, Thunnissen FB. Number and proliferation of basal
and parabasal cells in normal human airway epithelium. Am J Respir Crit
Care Med. 1998;157:2000–6.
12. Auerbach O, Forman JB, Gere JB, Kassouny DY, Muehsam GE, Petrick TG,
Smolin HJ, Stout AP. Changes in the bronchial epithelium in relation to
smoking and cancer of the lung; a report of progress. N Engl J Med. 1957;
256:97–104.
13. Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to
tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer.
2010;9:253.
14. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated
proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal
via beta-catenin signaling. Genes Dev. 2012;26:2271–85.
15. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical
significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006;
12:3057–63.
16. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G,
Spizzo G. High expression of TROP2 correlates with poor prognosis in
pancreatic cancer. Br J Cancer. 2008;99:1290–5.
17. Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S,
Matsubara H, Nomura F, Takiguchi M, Hiwasa T. Serological identification of
TROP2 by recombinant cDNA expression cloning using sera of patients with
esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029–35.
18. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S,
Rasse M, Laimer K. TROP2: a novel prognostic marker in squamous cell
carcinoma of the oral cavity. Mod Pathol. 2008;21:186–91.
19. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2
identifies a subpopulation of murine and human prostate basal cells with
stem cell characteristics. Proc Natl Acad Sci U S A. 2008;105:20882–7.
20. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell
of origin for human prostate cancer. Science. 2010;329:568–71.
21. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y, Tsujimura T,
Nakamura K, Miyajima A. Potential hepatic stem cells reside in EpCAM+ cells
of normal and injured mouse liver. Development. 2009;136:1951–60.
22. Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T,
Schafenacker AM, Huang J, Witte ON. Cell-autonomous activation of the
PI3-kinase pathway initiates endometrial cancer from adult uterine
epithelium. Proc Natl Acad Sci U S A. 2010;107:17298–303.
23. Hackett NR, Heguy A, Harvey BG, O’Connor TP, Luettich K, Flieder DB,
Kaplan R, Crystal RG. Variability of antioxidant-related gene expression in the
airway epithelium of cigarette smokers. Am J Respir Cell Mol Biol. 2003;29:
331–43.
24. Rock JR, Randell SH, Hogan BL. Airway basal stem cells: a perspective on
their roles in epithelial homeostasis and remodeling. Dis Model Mech. 2010;
3:545–56.
25. Ryan DM, Vincent TL, Salit J, Walters MS, Agosto-Perez F, Shaykhiev R,
Strulovici-Barel Y, Downey RJ, Buro-Auriemma LJ, Staudt MR, et al. Smoking
dysregulates the human airway basal cell transcriptome at COPD risk locus
19q13.2. PLoS One. 2014;9:e88051.
26. Shaykhiev R, Crystal RG. Early events in the pathogenesis of chronic
obstructive pulmonary disease. Smoking-induced reprogramming of airway
epithelial basal progenitor cells. Ann Am Thorac Soc. 2014;11(5):S252–258.
27. Crystal RG. Airway basal cells. The “smoking gun” of chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 2014;190:1355–62.
28. Shaykhiev R, Crystal RG. Basal cell origins of smoking-induced airway
epithelial disorders. Cell Cycle. 2014;13:341–2.
29. Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, Lattanzio R,
Piantelli M, Alberti S. The Trop-2 signalling network in cancer growth.
Oncogene. 2013;32:1594–600.
Liu et al. Respiratory Research  (2016) 17:159 Page 13 of 14
30. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van
Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al. Identification of a novel inhibitor of
mitogen-activated protein kinase kinase. J Biol Chem. 1998;273:18623–32.
31. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM,
Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway
obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;
350:2645–53.
32. Puchelle E, Zahm JM, Tournier JM, Coraux C. Airway epithelial repair,
regeneration, and remodeling after injury in chronic obstructive pulmonary
disease. Proc Am Thorac Soc. 2006;3:726–33.
33. Araya J, Cambier S, Markovics JA, Wolters P, Jablons D, Hill A, Finkbeiner W,
Jones K, Broaddus VC, Sheppard D, et al. Squamous metaplasia amplifies
pathologic epithelial-mesenchymal interactions in COPD patients. J Clin
Invest. 2007;117:3551–62.
34. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the
myofibroblast in focus. Chest. 2007;132:1311–21.
35. Wang Q, Wang Y, Zhang Y, Xiao W. The role of uPAR in epithelial-
mesenchymal transition in small airway epithelium of patients with chronic
obstructive pulmonary disease. Respir Res. 2013;14:67.
36. Milara J, Peiro T, Serrano A, Cortijo J. Epithelial to mesenchymal transition is
increased in patients with COPD and induced by cigarette smoke. Thorax.
2013;68:410–20.
37. Shaykhiev R, Zuo WL, Chao I, Fukui T, Witover B, Brekman A, Crystal RG. EGF
shifts human airway basal cell fate toward a smoking-associated airway
epithelial phenotype. Proc Natl Acad Sci U S A. 2013;110:12102–7.
38. Jonsdottir HR, Arason AJ, Palsson R, Franzdottir SR, Gudbjartsson T, Isaksson
HJ, Gudmundsson G, Gudjonsson T, Magnusson MK. Basal cells of the
human airways acquire mesenchymal traits in idiopathic pulmonary fibrosis
and in culture. Lab Invest. 2015;95:1418–28.
39. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8
and tumor necrosis factor-alpha in induced sputum from patients with
chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care
Med. 1996;153:530–4.
40. Kuschner WG, D’Alessandro A, Wong H, Blanc PD. Dose-dependent cigarette
smoking-related inflammatory responses in healthy adults. Eur Respir J.
1996;9:1989–94.
41. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J
Suppl. 2001;34:50s–9s.
42. Perotin JM, Adam D, Vella-Boucaud J, Delepine G, Sandu S, Jonvel AC,
Prevost A, Berthiot G, Pison C, Lebargy F, et al. Delay of airway epithelial
wound repair in COPD is associated with airflow obstruction severity. Respir
Res. 2014;15:151.
43. Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA repair and
aging in basal cell carcinoma: a molecular epidemiology study. Proc Natl
Acad Sci U S A. 1993;90:1614–8.
44. Bartling B. Cellular senescence in normal and premature lung aging. Z
Gerontol Geriatr. 2013;46:613–22.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Liu et al. Respiratory Research  (2016) 17:159 Page 14 of 14
